Dosage and administration
drink plenty of clear fluids to help prevent dehydration caused by diarrhea shake well before using use as directed per healthcare professional
drink plenty of clear fluids to help prevent dehydration caused by diarrhea shake well before using use as directed per healthcare professional
each 30 mL (6 tsp) contains: sodium 13 mg store between 20-25°C (68-77°F) See individual label or shipper label for lot number and expiration date.
1 mg/7.5 mL
2 mg/15 mL
Mint Flavor
For Hospital Use Only
Drug Facts
Loperamide HCl 1 mg
Anti-diarrheal
controls symptoms of diarrhea, including Travelers' Diarrhea
Do not use if you have ever had a rash or other allergic reaction to loperamide HCl
Do not use if you have bloody or black stool
Ask a doctor or pharmacist before use if you are taking antibiotics
These may be signs of a serious condition.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
anhydrous citric acid, carboxymethylcellulose sodium, D&C yellow no. 10, FD&C blue no. 1, glycerin, microcrystalline cellulose, natural and artificial mint flavor, propylene glycol, purified water, simethicone, sodium benzoate, sucralose, titanium dioxide, xanthan gum
Gluten Free
NDC 68094-107-62
7.5 mL per unit dose cup
Thirty (30) cups per shipper
NDC 68094-108-62
15 mL per unit dose cup
Thirty (30) cups per shipper
Manufactured By:
Perrigo Company
515 Eastern Avenue
Allegan, MI 49010
Packaged By:
Precision Dose, Inc.
722 Progressive Lane
South Beloit, IL 61080
LI911
Rev. 04/13
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0113-0645-26 | ML - Milliliter | 0113-0645 | 10550d3b-69cd-4d5b-bedc-243b8c35175a | 1 | 2013-02-13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Loperamide Hydrochloride | ACTIVE INGREDIENT | 77TI35393C | 1 | |
| Loperamide | ACTIVE MOIETY | 6X9OC3H4II | 1 | |
| anhydrous citric acid | INACTIVE INGREDIENT | XF417D3PSL | 1 | |
| carboxymethylcellulose sodium | INACTIVE INGREDIENT | K679OBS311 | 1 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| D&C Yellow No. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 1 | |
| FD&C Blue No. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| sodium benzoate | INACTIVE INGREDIENT | OJ245FE5EU | 1 | |
| sucralose | INACTIVE INGREDIENT | 96K6UQ3ZD4 | 1 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| xanthan gum | INACTIVE INGREDIENT | TTV12P4NEE | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68094-108 | 68094-108-59, 68094-108-62 |
| 0113-0645 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| xanthan gum | XANTHAN GUM | TTV12P4NEE | LOTION / TOPICAL | 6 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | POWDER, FOR SOLUTION / ORAL | 414 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | FILM, SOLUBLE / BUCCAL | 2 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | SPRAY / NASAL | 2 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / DENTAL | 2 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, METERED / RECTAL | NA | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INTRAVENOUS | 1152 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | TABLET, COATED / ORAL | 3.2 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GUM, CHEWING / BUCCAL | 24 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | TABLET, CHEWABLE / ORAL | 24.75 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | POWDER, FOR SUSPENSION / ORAL | 160 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | POWDER, FOR SUSPENSION / ORAL | 570 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SHAMPOO / TOPICAL | 0.75 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | TABLET, EXTENDED RELEASE / ORAL | 1 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, DELAYED RELEASE / ORAL | 1.7 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | SOLUTION / OPHTHALMIC | 0.6 %w/v | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | SYSTEM / TOPICAL | 2262 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, DELAYED RELEASE / ORAL | 366 mg | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / DENTAL | NA | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | PASTE, DENTIFRICE / DENTAL | 0.5 %w/w | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | SOLUTION/ DROPS / OPHTHALMIC | 2 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, LIQUID FILLED / ORAL | 12 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | FILM, SOLUBLE / ORAL | 7 mg | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | POWDER, FOR SUSPENSION / ORAL | 76 mg | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / ORAL | NA | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | FILM, SOLUBLE / ORAL | 33 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | SYRUP / ORAL | 80 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1800 mg | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | DOUCHE / VAGINAL | NA | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / ORAL | 27120 mg | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / ORAL | 27.53 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION / TOPICAL | 4.35 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | SOLUTION / OPHTHALMIC | 1 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SYRUP / ORAL | 0.05 mg/5ml | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 48 mg | ||
| FD&C Blue No. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 0.01 mg | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SUSPENSION / ORAL | 20 mg/5ml |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091292-001 | LOPERAMIDE HYDROCHLORIDE | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 | d4dbc9d85df4… | ||
| 2026-10-15 13:18:30 | 2026-09 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SOLUTION / ORAL | 2011-05-20 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A091292-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/7.5ML | SUSPENSION / ORAL | 2011-05-20 | 3bdfa0b2c4d7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| afc39923-15e4-4abe-bb17-5571475605de | 45b3d2da-5321-4188-a011-281d1ee3cbfa | 2019-06-20 | Warnings | afc39923-15e4-4abe-bb17-5571475605de 45b3d2da-5321-4188-a011-281d1ee3cbfa |
Adverse event summaries are temporarily unavailable. Other product information remains available.